$VTEX

Gomide de Faria Mariano sold $19K of VTEX (indirect holdings)

Gomide de Faria Mariano (Chief Executive Officer) sold 4,808 indirectly-held shares of VTEX (VTEX) at $4.01 on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gomide de Faria Mariano
Published Jul 29, 2026, 7:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 7:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VTEX
Neutral
high confidence
Mentioned
$VTEX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VTEXNeutralLow
01

Why it matters

This is primarily a sentiment and positioning datapoint rather than a fundamental update. Traders may monitor for follow-on filings or changes in insider activity patterns, but no new business or financial information is provided.

02

Market read

Discloses a CEO open-market sale (4,808 shares, $19,280.08) under a pre-arranged 10b5-1 plan, which is typically low-signal for valuation.

03

What to watch

The article does not state whether the CEO’s total holdings changed materially over time, nor does it provide context on planned sale schedules or tax-related motives beyond the existence of a 10b5-1 plan.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-29, disclosing a 2026-07-27 insider sale.

Background

The article is an SEC Form 4 insider transaction disclosure for VTEX, reported as an open-market sale by the CEO via an indirect holding structure.

Company-level read

Ticker impact

$VTEXNeutralHigh confidence
Context

SEC Form 4 shows CEO Gomide de Faria Mariano sold 4,808 shares of VTEX at $4.01 on 2026-07-27 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a disclosed open-market sale by the CEO, explicitly under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal, as this is company-specific insider transaction disclosure without operational or financial guidance changes.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as confidence erosion, especially if paired with other negative signals not present here.

Key entities

  • VTEX

    Company whose CEO insider sale is disclosed on SEC Form 4.

  • Gomide de Faria Mariano

    VTEX CEO who sold 4,808 shares at $4.01 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VTEXMed

VTEX (VTEX) Just Turned A Profit Corner, But Growth Is Slowing

VTEX (NYSE:VTEX) reported Q2 2026 results showing improved profitability with non-GAAP income from operations up 62.4% YoY to $13.8M, and free cash flow up 79.1% to $12.7M. However, revenue growth slowed to 1.3% YoY on an FX-neutral basis, with management expecting flat growth for Q3. The company repurchased 6.2M shares for $23.2M during the quarter.

$VTEXMedAI 8/10

VTEX (VTEX) Q2 2026 Earnings Call Transcript

VTEX reported Q2 2026 results in an earnings call. GMV was $5.7B, up 7% FX-neutral. Subscription revenue was $63.8M, up 1.3% FX-neutral. Non-GAAP operating income rose 62% to $13.8M, with a 21.4% margin. Free cash flow was $12.7M, up 79%. Q3 guidance calls for flat FX-neutral subscription growth.

$VTEXMedAI 8/10

VTEX Q2 Earnings Call Highlights

VTEX (NYSE:VTEX) reported Q2 margin and cash flow improvement and guided for Q3 and full-year low-single-digit FX-neutral subscription revenue growth and low-20% non-GAAP operating and free cash flow margins. Q2 non-GAAP subscription gross margin rose to 81.8%. Free cash flow rose 79% to $12.7M. VTEX repurchased 6.2M shares at $3.76.

$VTEXMed

VTEX (VTEX): Financial results for Q2 2026

VTEX (VTEX) furnished an SEC Form 6-K — earnings release. VTEX Reports Second Quarter 2026 Financial Results Subscription revenue grew 11.4% (+1.3% FXN), with GMV up 17.8% (+7.0% FXN) Non-GAAP income from operations increased 62.4% to US$13.8 million, reaching a 21.4% margin Free cash flow increased 79.1% to US$12.7 million, reaching a